Table 1 Demographic and clinical characteristics of study participants
Variables | All patients (N = 492) | Patients with MB (N = 76) | Patients without MB (N = 416) | p value |
|---|---|---|---|---|
No. of males, n | 288 (59%) | 53 (70%) | 235 (56%) | 0.031 |
Age, years | 45.7 ± 13.8 | 37.2 ± 13.6 | 47.2 ± 13.3 | < 0.001 |
BMI, Kg/m2 | 24.9 ± 3.7 | 23.3 ± 3.8 | 25.3 ± 3.6 | < 0.001 |
Dyspnea, n | 394 (80%) | 59 (78%) | 335 (81%) | 0.561 |
Chest pain, n | 135 (27%) | 21 (28%) | 114 (27%) | 0.967 |
Syncope, n | 111 (23%) | 22 (29%) | 89 (21%) | 0.147 |
NYHA III/IV, n | 397 (81%) | 59 (78%) | 338 (81%) | 0.462 |
Hypertension, n | 95 (19%) | 5 (7%) | 90 (22%) | 0.002 |
Diabetes mellitus, n | 16 (3%) | 1 (1%) | 15 (4%) | 0.301 |
Beta blocker, n | 371 (75%) | 59 (78%) | 312 (75%) | 0.624 |
CCB, n | 53 (11%) | 8 (11%) | 45 (11%) | 0.940 |
LAD, mm | 42.1 ± 8.3 | 41.1 ± 8.4 | 42.3 ± 8.3 | 0.247 |
LVEDD, mm | 45.7 ± 5.0 | 45.5 ± 4.9 | 45.8 ± 5.0 | 0.673 |
Maximal WT, mm | 26.0 ± 7.7 | 26.7 ± 6.5 | 25.9 ± 7.9 | 0.377 |
LVEDVi, ml/m2 | 72.9 (62.5–87.0) | 70.3 (62.1–87.6) | 73.0 (62.6–87.0) | 0.774 |
LV mass I, g/m2 | 90.5 (71.4–119.3) | 92.2 (69.7–131) | 90.1 (71.5–118.3) | 0.359 |
LGE mass I, g/m2 | 7.3 (3.1–15.9) | 8.7 (4.0–22.4) | 7.0 (2.8–14.7) | 0.022 |
LGE, % of LV mass | 8.1 (3.6–16.1) | 10.3 (5.1–19.1) | 7.7 (3.3–15.5) | 0.032 |
LVEF, % | 71.3 ± 6.3 | 71.4 ± 5.7 | 71.3 ± 6.4 | 0.904 |
Maximal LVOTG, mmHg | 81.2 ± 27.3 | 76.7 ± 30.0 | 82.0 ± 26.7 | 0.121 |